MYL(SH:600993) Xin Lang Cai Jing·2025-11-17 00:24Core Insights - The company reported steady growth in its financial performance for Q3 2025, with a revenue of 8.88 billion yuan, a year-on-year increase of 2.80%, and a net profit attributable to shareholders of 1.58 billion yuan, up 8.38% year-on-year [1][2] - The company is actively enhancing its pharmaceutical operating capabilities and cultivating new growth drivers, particularly in the retail sector and through the development of specialized products [3] Financial Performance - For the first nine months of 2025, the company achieved a total revenue of 28.37 billion yuan, reflecting a year-on-year growth of 1.63%, and a net profit attributable to shareholders of 5.01 billion yuan, which is a 9.51% increase year-on-year [1] - In Q3 2025, the gross profit margin was reported at 48.00%, an increase of 1.52 percentage points year-on-year, while the net profit margin was 17.76%, up 0.91 percentage points year-on-year [2] - Sales expenses for Q3 2025 were 2.17 billion yuan, a year-on-year increase of 12.54%, with a sales expense ratio of 24.43%, up 2.12 percentage points [2] Strategic Initiatives - The company is focusing on key retail chains and products, enhancing resource investment, and conducting marketing activities to strengthen its position in the anorectal market [3] - The company is advancing the development of its unique ophthalmic products and expanding into related health and beauty segments, creating a comprehensive product structure in the eye care category [3] Profit Forecast - The company forecasts net profits attributable to shareholders of 6.08 billion yuan, 7.17 billion yuan, and 8.21 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding EPS of 1.41 yuan, 1.66 yuan, and 1.90 yuan [3]